The potential of phosphodiesterase 4 inhibitors for the treatment of depression: Opportunities and challenges

Current Opinion in Investigational Drugs

Volumn 5, Issue 1, 2004, Pages 34-39

  Renau, Thomas E ^a  

^a ROCHE BIOSCIENCE   (United States)

Author keywords

BDNF; CREB; Emesis; Neuroplasticity; Rolipram

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CILOMILAST; CYCLIC AMP; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DESIPRAMINE; GLUCOCORTICOID RECEPTOR; IMIPRAMINE; MONOAMINE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; ROFLUMILAST; ROLIPRAM; SEROTONIN; TRICYCLIC ANTIDEPRESSANT AGENT; TYROSINE KINASE RECEPTOR; ZARDAVERINE;

ASTHMA; CELL FUNCTION; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DEPRESSION; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG BINDING; DRUG EFFICACY; DRUG INDUSTRY; DRUG MECHANISM; DRUG TOLERABILITY; DRUG USE; ENTERITIS; HUMAN; INFLAMMATORY DISEASE; MAJOR DEPRESSION; MODULATION; MOOD DISORDER; MULTIPLE SCLEROSIS; NAUSEA; NERVE CELL PLASTICITY; NONHUMAN; REVIEW; RHEUMATOID ARTHRITIS; SECOND MESSENGER; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VOMITING;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MONOAMINE OXIDASE INHIBITORS; PHOSPHODIESTERASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; VOMITING;

EID: 2342442163     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Francis SH, Turko IV, Corbin JD: Cyclic nucleotids phoshodiesterases: Relating structure and function. Prog Nucleic Acid Res Mol Boil (2001) 65:1-52.
2. Torphy TJ: Phosphodiesterase isozymes: Molecular targets for novel antiasthma agents. Am J Respir Crit Care Med (1998) 157(2):351-370.
3. Houslay MD, Sullivan M, Bolger GB: The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: Intracellular targeting, regulation and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv Pharmacol (1998) 44:225-342.
4. Houslay MD, Adams DR: PDE4 cAMP phosphodiesterases: Modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J (2003) 370(1):1-18.
5. Conti M, Richter W, Mehats C, Livera G, Park J-Y, Jin C: Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem (2003) 278(8):5493-5496.
6. Xu RX, Hassell AM, Vanderwall D, Lambert MH, Holmes WD, Luther MA, Rocque WJ, Milburn MV, Zhao Y, Ke H, Nolte RT: Atomic structure of PDE4: Insights into phosphodiesterase mechanism and specificity. Science (2000) 288(5472):1822-1825.
7. Lee ME, Markowitz J, Lee JO, Lee H: Crystal structure of phosphodiesterase 4D and inhibitor complex. FEBS Lett (2002) 530(1-3):53-58.
8. Huai Q, Wang H, Sun Y, Kim H-Y, Liu Y, Ke H: Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity. Structure (2003) 11(7):865-873.
9. Burnouf C, Pruniaux M-P: Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr Pharm Des (2002) 8(14):1255-1296.
10. Dyke HJ, Montana JG: Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Investig Drugs (2002) 11(1):1-13.
11. Cherry JA, Davis RL: Cyclic AMP phosphodiesterases are localized in regions of the mouse brain associated with reinforcement, movement and affect. J Comp Neurol (1999) 407(2):287-301.
12. Manji HK, Quiroz JA, Sporn J, Payne JL, Denicoff K, Gray NA, Zarate CA Jr, Charney DS: Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry (2003) 53(8):707-742.
13. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM: Neurobiology of depression. Neuron (2002) 34(1):13-25.
14. Manji HK, Drevets WC, Charney DS: The cellular neurobiology of depression. Nat Med (2001) 7(5):541-547.
15. Duman RS, Heninger GR, Nestler EJ: A molecular and cellular theory of depression. Arch Gen Psychiatry (1997) 54(7):597-606.
16. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science (2003) 301(5634):805-809.
17. Nakagawa S, Kim J-E, Lee R, Malberg JE, Chen J, Steffan C, Zhang Y-J, Nestler EJ, Duman RS: Regulation of neurogenesis in adult mouse hippocampus by cAMP and cAMP response element-binding protein. J Neurosci (2002) 22(9):3673-3682.
18. Zubenko GS, Hughes HB III, Stiffler JS, Brechbiel A, Zubenko WN, Maher BS, Marazita ML: Sequence variations in CREB1 cosegregate with depressive disorders in women. Mol Psychiatry (2003) 8(6):611-618.
19. Nibuya M, Nestler EJ, Duman RS: Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci (1996) 16(7):2365-2372.
20. Dowlatshahi D, MacQueen GM, Wang JF, Young LT: Increased temporal cortex CREB concentrations and antidepressant treatment in major depression. Lancet (1998) 352(9142):1754-1755.
21. Chen AC-H, Shirayama Y, Shin K-H, Neve RL, Duman RS: Expression of the cAMP response element binding protein (CREB) in hippocampus produces an antidepressant effect. Biol Psychiatry (2001) 49(9):753-762.
22. Nibuya M, Morinobu S, Duman RS: Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci (1995) 15(11):7539-7547.
23. Conti AC, Cryan JF, Dalvi A, Lucki I, Blendy JA: cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J Neurosci (2002) 22(8):3262-3268.
24. Xu H, Richarson JS, Li X-M: Dose-related effects of chronic antidepressants on neuroprotective proteins BDNF, Bcl-2 and Cu/Zn-SOD in rat hippocampus. Neuropsychopharmacology (2003) 28(1):53-62.
25. Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM: Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav (1997) 56(1):131-137.
26. Shirayama Y, Chen AC-H, Nakagawa S, Russell DS, Duman RS: Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci (2002) 22(8):3251-3261.
27. Coppell AL, Pei Q, Zetterström TSC: Bi-phasic change in BDNF gene expression following antidepressant drug treatment. Neuropharmacology (2003) 44(7):903-910.
28. Miller AH, Vogt GJ, Pearce BD: The phosphodiesterase type 4 inhibitor, rolipram, enhances glucocorticoid receptor function. Neuropsychopharmacology (2002) 27(6):939-948.
29. Zhu J, Mix E, Winblad B: The antidepressant and anti-inflammatory effects of rolipram in the central nervous system. CNS Drug Rev (2001) 7(4):387-398.
30. Wachtel H: Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′,5′-monophosphate phosphodiesterase inhibitors. Neuropharmacology (1983) 22(3):267-272.
31. O'Donnell JM: Antidepressant-like effects of rolipram and other inhibitors of cyclic adenosine monophosphate phosphodiesterase on behavior maintained by differential reinforcement of low response rate. J Pharmacol Exp Ther (1993) 264(3):1168-1178.
32. O'Donnell JM, Frith S: Behavioral effects of family-selective inhibitors of cyclic nucleotide phosphodiesterases. Pharmacol Biochem Behav (1999) 63(1):185-192.
33. Fujimaki K, Morinobu S, Duman RS: Administration of a cAMP phosphodiesterase 4 inhibitor enhances antidepressant-induction of BDNF mRNA in rat hippocampus. Neuropsychopharmacology (2000) 22(1):42-51.
34. Saccomano NA, Vinick FJ, Koe BK, Nielsen JA, Whalen WM, Meltz M, Phillips D, Thadieo PF, Jung S, Chapin DS, Lebel LA et al: Calcium-independent phosphodiesterase inhibitors as putative antidepressants: [3-(bicycloalkyloxy)-4-methoxyphenyl]2-imidazolidinones. J Med Chem (1991) 34(1):291-298.
35. Horowski R, Sastere-y-Hernandez M: Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: Global evaluation of the preliminary reports. Curr Ther Res (1985) 38(1):23-29.
36. Zeller E, Stief HJ, Pflug B, Sastre-y-Hernandez M: Results of a phase II study of the antidepressant effect of rolipram. Pharmacopsychiatry (1984) 17(6):188-190.
37. Laux G, Becker T, Kühne G, Lesch K-P, Riederer P, Beckmann H: Clinical and biochemical effects of the selective phosphodiesterase inhibitor rolipram in depressed inpatients controlled by determination of plasma level. Pharmacopsychiatry (1988) 21(6):378-379.
38. Bertolino A, Crippa D, Di Dio S, Fichte K, Musmeci G, Porro V, Rapisarda V, Sastre-y-Hernandez M, Schratzer M: Rolipram versus imipramine in inpatients with major, "minor" or atypical depressive disorder: A double-blind double-dummy study aimed at testing a novel therapeutic approach. Int Clin Psychopharmacol (1988) 3(3 ):245-253.
39. Herbestreit GF, Fellerer K, Fichte K, Fischer G, Geyer N, Meya U, Sastre-y-Hernandez M, Schöny W, Schratzer M, Soukop W, Tramptisch E et al: Rolipram in major depressive disorder: Results of a double-blind comparative study with imipramine. Pharmacopsychiatry (1989) 22:156-160.
40. Scott AI, Perini AF, Shering PA, Whalley LJ: In-patient major depression: Is rolipram as effective as amitriptyline? Eur J Clin Pharmacol (1991) 40(2):127-129.
41. Bobon D, Breulet M, Gerard-Vandenhove MA, Guiot-Goffioul F, Plomteux G, Sastre-y-Hernandez M, Schratzer M, Troisfontaines B, von Frenckell R, Wachtel H: Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives. Eur Arch Psychiatry Neurol Sci (1988) 238(1):2-6.
42. Burnouf C, Pruniaux M-P, Szilagyi CM: Phosphodiesterases 4 inhibitors. Annu Rep Med Chem (1998) 33:91-109.
43. Laliberte F, Han Y, Govindarajan A, Giroux A, Liu S, Bobechko B, Lario P, Bartlett A, Gorseth E, Gresser M, Huang Z: Conformational difference between PDE4 apoenzyme and holoenzyme. Biochemistry (2000) 39(21):6449-6458.
44. Liu S, Laliberte F, Bobechko B, Bartlett A, Lario P, Gorseth E, Van Hamme J, Gresser MJ, Huang Z: Dissecting the cofactor-dependent and independent bindings of PDE4 inhibitors. Biochemistry (2001) 40(34):10179-10186.
45. Robichaud A, Savoie C, Stamatiou PB, Lachance N, Jolicoeur P, Rsori R, Chan CC: Assessing the emetic potential of PDE4 inhibitors in rats. Br J Pharmacol (2002) 135(1):113-118.
46. Robichaud A, Stamatiou PB, Jin S-LC, Lachance N, MacDonald D, Laliberté F, Liu S, Huang Z, Conti M, Chan C-C: Deletion of phosphodiesterase 4D in mice shortens α2-adrenoreceptor-mediated anesthesia, a behavioral correlate of emesis. J Clin Invest (2002) 110(7):1045-1052.
47. Miró X, Pérez-Torres S, Puigdomènech P, Palacios JM, Mengod G: Differential distribution of PDE4D splice variant mRNAs in rat brain suggests association with specific pathways and presynaptical localization. Synapse (2002) 45(4):259-269.
48. Zhang H-T, Huang Y, Jin S-LC, Frith SA, Suvarna N, Conti M, O'Donnell JM: Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology (2002) 27(4):587-595.